Literature DB >> 17013643

Giant cell tumour of bone: morphological, biological and histogenetical aspects.

Mathias Werner1.   

Abstract

The giant cell tumour of bone (GCT) is a locally aggressive intraosseous neoplasm of obscure biological behaviour. Although well defined in clinical, radiological and histological terms, detailed information on its biological development is still relatively incomplete. The tumoral tissue consists of three cell types--the neoplastic giant cell tumour stromal cells (GCTSC), representing the proliferative fraction, secondarily recruited mononuclear histiocytic cells (MNHC) and multinuclear giant cells (MNGC). These cellular components interact together with factors that have a role in regulating osteoclast function in normal bone tissue (e.g. RANK, RANKL, OPG, M-CSF). Recent publications suggest that the neoplastic stromal cells express differentiation features of mesenchymal stem cells. Further research of the pathogenesis of GCT as well as the complex interactions of its cellular populations may provide the knowledge necessary for developing approaches for a biological-based therapy of this neoplasm.

Entities:  

Mesh:

Year:  2006        PMID: 17013643      PMCID: PMC3172738          DOI: 10.1007/s00264-006-0215-7

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  60 in total

1.  Extraosseous primary and recurrent giant cell tumors: transforming growth factor-beta1 and -beta2 expression may explain metaplastic bone formation.

Authors:  L A Teot; R J O'Keefe; R N Rosier; J X O'Connell; E J Fox; D G Hicks
Journal:  Hum Pathol       Date:  1996-07       Impact factor: 3.466

2.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

3.  Giant cell tumor of bone. Prognosis and treatment of pulmonary metastases.

Authors:  J C Cheng; J O Johnston
Journal:  Clin Orthop Relat Res       Date:  1997-05       Impact factor: 4.176

4.  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.

Authors:  V Kartsogiannis; H Zhou; N J Horwood; R J Thomas; D K Hards; J M Quinn; P Niforas; K W Ng; T J Martin; M T Gillespie
Journal:  Bone       Date:  1999-11       Impact factor: 4.398

5.  Human osteoclastoma-derived stromal cells: correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo.

Authors:  I E James; R A Dodds; D L Olivera; M E Nuttall; M Gowen
Journal:  J Bone Miner Res       Date:  1996-10       Impact factor: 6.741

6.  Benign giant cell tumor of bone with osteosarcomatous transformation ("dedifferentiated" primary malignant GCT): report of two cases.

Authors:  E W Brien; J M Mirra; S Kessler; M Suen; J K Ho; W T Yang
Journal:  Skeletal Radiol       Date:  1997-04       Impact factor: 2.199

7.  Expression of osteoclast differentiation signals by stromal elements of giant cell tumors.

Authors:  G J Atkins; D R Haynes; S E Graves; A Evdokiou; S Hay; S Bouralexis; D M Findlay
Journal:  J Bone Miner Res       Date:  2000-04       Impact factor: 6.741

8.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

9.  Giant cell tumor of bone: a clinicopathologic study of prognostic factors.

Authors:  F Masui; S Ushigome; K Fujii
Journal:  Pathol Int       Date:  1998-09       Impact factor: 2.534

10.  Control of cell cycle gene expression in bone development and during c-Fos-induced osteosarcoma formation.

Authors:  A Sunters; J McCluskey; A E Grigoriadis
Journal:  Dev Genet       Date:  1998
View more
  70 in total

1.  Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPβ - MafB axis.

Authors:  Jeske J Smink; Per-Ulf Tunn; Achim Leutz
Journal:  J Mol Med (Berl)       Date:  2011-11-10       Impact factor: 4.599

2.  Intratibial injection of patient-derived tumor cells from giant cell tumor of bone elicits osteolytic reaction in nude mouse.

Authors:  Leqin Xu; Zhipeng Wu; Zhenhua Zhou; Xinghai Yang; Jianru Xiao
Journal:  Oncol Lett       Date:  2018-07-16       Impact factor: 2.967

3.  Image-guided multilevel vertebral osteotomies for en bloc resection of giant cell tumor of the thoracic spine: case report and description of operative technique.

Authors:  Sheila M Smitherman; Claudio E Tatsui; Ganesh Rao; Garrett Walsh; Laurence D Rhines
Journal:  Eur Spine J       Date:  2010-01-13       Impact factor: 3.134

4.  The diagnostic value of needle biopsy for musculoskeletal lesions.

Authors:  Ki-Sun Sung; Sung-Wook Seo; Min-Soo Shon
Journal:  Int Orthop       Date:  2009-08-05       Impact factor: 3.075

5.  Treatment and outcome of malignant giant cell tumor in the spine.

Authors:  Huabin Yin; Mo Cheng; Bo Li; Binbin Li; Peng Wang; Tong Meng; Jing Wang; Wang Zhou; Wangjun Yan; Jianru Xiao
Journal:  J Neurooncol       Date:  2015-06-04       Impact factor: 4.130

6.  Reconstruction of distal radius by fibula following excision of grade III giant cell tumour: follow-up of 18 cases.

Authors:  Sun Peng-Fei; Jia Yu-Hua
Journal:  Int Orthop       Date:  2010-02-14       Impact factor: 3.075

Review 7.  An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma.

Authors:  Mojdeh Safari; Alireza Khoshnevisan
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

8.  The hypermetabolic giant: 18F-FDG avid giant cell tumor identified on PET-CT.

Authors:  Wendi O'Connor; Megan Quintana; Scott Smith; Monte Willis; Jordan Renner
Journal:  J Radiol Case Rep       Date:  2014-06-30

Review 9.  Giant cell formation and function.

Authors:  William G Brodbeck; James M Anderson
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

10.  A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases.

Authors:  Ira J Miller; Alan Blank; Suellen M Yin; Allison McNickle; Robert Gray; Steven Gitelis
Journal:  Diagn Pathol       Date:  2010-09-22       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.